Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPHA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPHA2 ECD-Fc Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View EPHA2 Products |
| Gene Delivery | EPHA2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based conformation assays. |
View EPHA2 Products |
| Benchmark Ab | Anti-EPHA2 Biosimilar (Recombinant Sequence) Recombinant positive control for binding and internalization assays. |
View EPHA2 Products |
| Validator | EPHA2 siRNA Set For target knockdown verification and specificity controls. |
View EPHA2 Products |
| Related Target A | EFNA1 Natural ligand for ligand-competition assays and receptor activation studies. |
View EFNA1 Products |
| Related Target B | EGFR Synergistic receptor tyrosine kinase; co-targeted to bypass drug resistance in solid tumors. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter screening | Eph receptor homolog panel (EPHA1, EPHA3, EPHA4) strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live EPHA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPHA2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting internalization-dependent delivery mechanisms and bispecific formats to mitigate off-target toxicities in normal tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | AstraZeneca, MedImmune | Solid Tumors, NSCLC | Internalization Assay (Need high-purity HEK293-expressed ECD-Fc) |
| PDC (Peptide-Drug Conjugate) | Bicycle Therapeutics | Ovarian Cancer, Sarcoma | High-throughput Affinity Screening (Need sequence-verified monomeric EPHA2) |
| CAR-T / Cell Therapy | Academic Institutions, Biotech | Glioblastoma, Pediatric Glioma | Cell-surface Conformation Validation (Need Lentivirus for Stable Cell Lines) |